The clinical and commercial success of checkpoint combinations is driving pharma and biotech to invest heavily in immune checkpoint inhibitor drug pipelines. However, combinations involving IO therapies have stolen the spotlight due to the dramatic impact they have had in many late-stage programs. With over 2000 clinical trials underway, the race to be the next to market is more competitive than ever
The ICI-IO Combinations Summit will bring together senior decision makers from drug developer organizations who are committed to optimizing the development of IO combination therapies.
So, who will you meet?
The new face of the ICI series has revealed a wave of opportunity for IO-based solution providers. If you have capabilities that would benefit our audience in this space, this meeting will provide a unique platform to showcase your solutions, generate new business leads and source opportunities for partnerships.
“This conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics.”
Act now to stay ahead of the curve and seize the wealth of opportunity on offer.
Email email@example.com for more information about the partnership opportunities available which will deliver on your commercial objectives this year.